Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
NCT03522545

Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

Led by The University of Texas Health Science Center, Houston · Updated on 2025-06-22

30

Participants Needed

1

Research Sites

240 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).

CONDITIONS

Official Title

Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of Bipolar I or Bipolar II disorder as confirmed by semi-structured interviews
  • Age between 18 and 65 years
  • Current depressive episode with Montgomery-Åsberg Depression Rating Scale (MADRS) score of 25 or above
  • Treatment resistance defined as failure to respond to two trials of mood stabilizers or antidepressants
  • C-reactive protein (CRP) concentration greater than 5 mg/L
  • Female participants must not be pregnant, breastfeeding, or planning pregnancy and must use reliable contraception if of childbearing potential
  • Ability to provide informed consent
  • Fluent in English to complete neurocognitive testing
  • Signed written informed consent
Not Eligible

You will not qualify if you...

  • Receipt of MSCs transplant within the last six months
  • Inability to follow study procedures
  • High suicidal risk
  • History of brain injury, neurologic impairment, seizure disorder requiring anti-convulsants, renal or hepatic disease with abnormal lab values, immunosuppression, HIV, splenectomy, or cancer
  • Serious unstable medical conditions or conditions affecting neuropsychological assessment such as Parkinson's disease, multiple sclerosis, stroke, substance abuse
  • Hemodynamic instability at time of MSCs infusion
  • Positive pregnancy test at screening or baseline

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The University of Texas Health Science Center at Houston

Houston, Texas, United States, 77054

Actively Recruiting

Loading map...

Research Team

D

Dana Razouq

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression | DecenTrialz